Product category |
|
Therapeutic indication |
|
Dosing |
|
Efficacy |
|
Key features |
|
Challenges |
|
Status |
- The Global Fund ERP approved for one year until Feb 2020
- Registered in 4 countries; ongoing in 5 other countries
- Orders confirmed for >11 million treatments in 2019
|
Next milestone |
WHO prequalification Extension of the recommendation for children up to their 10th birthday Validation of the dose and development of a specific packaging for children from 5 years old up until their 10th birthday Exploration of expanded SMC coverage by adding a fifth monthly round of treatment in areas with longer seasonal transmission
|
MMV Project Director |
|